SRX Global announces UC Davis as new site for CERo’s Phase 1 CER-1236 trial
SRXH•SRX Global announced UC Davis as a new site for CERo Therapeutics’ Phase 1 trial of CER-1236 in blood cancers. UC Davis already manufactures the treatment, and adding enrollment is expected to expand recruitment capacity and streamline treatment logistics.
1. Trial site added
UC Davis has joined the ongoing Phase 1 CERTAIN-T trial of CER-1236 in blood cancers. The university already manufactures CER-1236, and adding patient enrollment is expected to expand recruitment capacity and streamline treatment logistics. Previously reported preliminary results showed clinical improvement in two patients, with no dose-limiting toxicities or treatment-related severe adverse events during assessment; formal response assessments were ongoing, and the findings were insufficient to establish safety or efficacy. The expansion follows an October 7, 2026, agreement to acquire CERo Therapeutics, subject to customary closing conditions.
